Fig. 6: ARB suppressed osteoblast differentiation from BdCs of r-axSpA patients. | Experimental & Molecular Medicine

Fig. 6: ARB suppressed osteoblast differentiation from BdCs of r-axSpA patients.

From: Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis

Fig. 6

a–c BdCs of the controls and r-axSpA patients were differentiated into osteoblasts using an ARB (1 × 10−5 M losartan) or ACEi (1 × 10−5 M captopril). a ALP staining (left) and ALP activity (right). b ARS and Von Kossa staining (left) and quantification (right). c HA staining (left) and quantification (right). Scale bar = 200 µm. ACEi, angiotensin-converting enzyme inhibitor; ALP, alkaline phosphatase; Ang, angiotensin; ARB, angiotensin II receptor blocker; ARS, alizarin red; AT1R, angiotensin II type 1 receptor; BdCs, bone-derived cells; HA, hydroxyapatite. Values are presented as the mean ± S.D.; *p < 0.05, **p < 0.01, ***p < 0.001 using the Mann‒Whitney U test.

Back to article page